| Website | newhavenpharma.com |
| Category | BioTech |
| Phone | 770-329-0074 |
| Employees |
| TOTAL | $6M |
| FUNDING TOTAL | $6M |
| Series A, 10/12 Connecticut Innovations EJ Funds Kuzari Group Advantage Capital Partners | $6M |
| DEBT TOTAL | $2M |
| Debt, 4/13 Horizon Technology Finance Management LLC | $2M |
New Haven Pharmaceuticals (NHP) is a specialty pharmaceuticals company developing proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications that represent significant market opportunities. The company’s novel product pipeline employs proprietary, oral, controlled-release technologies, as well as intellectual property licensed from Yale University, which will enable optimal dosing, safety, efficacy and patient convenience.
